α-Synuclein in Parkinson's disease: getting to the core of the matter. Lancet Neurol 2015;14:785-6.
Hauser, RA. 2015. “α-Synuclein in Parkinson’s Disease: Getting to the Core of the Matter. Lancet Neurol 2015;14:785-6.”. Lancet Neurol.
Search
Search results
1963 results found
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol 2015;72:1491-500.
Hauser, RA, F Stocchi, O Rascol, SB Huyck, R Capece, TW Ho, P Sklar, C Lines, D Michelson, and D Hewitt. 2015. “Preladenant As an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol 2015;72:1491-500.”. JAMA Neurol.
Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord 2015;30:1371-81.
Simuni, T, C Caspell-Garcia, C Coffey, LM Chahine, S Lasch, WH Oertel, G Mayer, et al. 2015. “Correlates of Excessive Daytime Sleepiness in de Novo Parkinson’s Disease: A Case Control Study. Mov Disord 2015;30:1371-81.”. Mov Disord.
Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014;4:57-65.
Hauser, RA, LA Arthur Hewitt, and S Isaacson. 2014. “Droxidopa in Patients With Neurogenic Orthostatic Hypotension Associated With Parkinson’s Disease (NOH306A). J Parkinsons Dis 2014;4:57-65.”. J Parkinsons Dis.
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 2014;29:75-82.
LeWitt, PA, FJ Huff, RA Hauser, D Chen, D Lissin, K Zomorodi, and KC Cundy. 2014. “Double-Blind Study of the Actively Transported Levodopa Prodrug XP21279 in Parkinson’s Disease. Mov Disord 2014;29:75-82.”. Mov Disord.
Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 2014;20:1171-6.
Hauser, RA, S Isaacson, T Clinch, and Tigan/Apokyn Study Investigators. 2014. “Randomized, Placebo-Controlled Trial of Trimethobenzamide to Control Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine Injection. Parkinsonism Relat Disord 2014;20:1171-6.”. Parkinsonism Relat Disord.
Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol 2013;20:180-7.
AH, Schapira, P Barone, RA Hauser, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, and W Poewe. 2013. “Success Rate, Efficacy, and Safety/Tolerability of Overnight Switching from Immediate- to Extended-Release Pramipexole in Advanced Parkinson’s Disease. Eur J Neurol 2013;20:180-7.”. Eur J Neurol.
Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013;28:1823-31.
IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother. 2012;12:133-40.
Hauser, RA. 2012. “IPX066: a Novel Carbidopa-Levodopa Extended-Release Formulation. Expert Rev Neurother. 2012;12:133-40.”. Expert Rev Neurother.
Design innovations and baseline findings in a long-term Parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson’s Disease Long-Term Study-1. Mov Disord 2012; 27:1513-1521.
Elm, JJ, and The NINDS NET-PD Investigators. 2012. “Design Innovations and Baseline Findings in a Long-Term Parkinson’s Trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson’s Disease Long-Term Study-1. Mov Disord 2012; 27:1513-1521.”. Mov Disord.